Device Trial Radar · NCT05574777
Endoscopic Gastric Mucosal Ablation (GMA) of Class III Obesity
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Apr 13, 2023
Primary completion
Aug 22, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Erbe Elektromedizin GmbHNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Erbe do Brasil Chirúrgicos e Endoscópicos LTDA; Bioscience Consulting, Inc.
- First posted
- Oct 12, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to investigate safety and feasibility of a new weight loss technique called Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure. Previous studies have suggested that weight loss after vertical sleeve gastrectomy (VSG) is partly due to the removal of normal stomach tissue suspected of having hormonal function. The study will investigate the minimally invasive treatment of obesity Class III participants by means of argon plasma coagulation (APC) in combination with waterjet submucosal injection using HybridAPC. As primary endpoint device or procedure related occurrence of complications according to Clavien-Dindo classification will be determined. After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. If a participant is confirmed to be a suitable candidate additional tests will be performed prior to the first application of GMA to assess the health status of the participant prior to treatment. During the screening and baseline visit the medical history and the medications of the participant will be reviewed. After the treatments the participants will be followed for up to 6 months to assess the outcome of the GMA procedure.
Conditions
- Adiposity
- Morbid
- Obesity
Interventions
Hybrid Argonplasma coagulation (HAPC)Device
Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of complications related to the device or procedureTime frame: 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.